title: Early clinical experience with subcutaneous GR43175 in acute migraine: an overview.
abstract: In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.
authors.affiliation: Department of Neurology, University Hospital, Gentofte, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Tfelt-Hansen
authors.forename: J
authors.initials: J
authors.lastname: Brand
authors.forename: P
authors.initials: P
authors.lastname: Dano
authors.forename: A
authors.initials: A
authors.lastname: Doenicke
authors.forename: L J
authors.initials: LJ
authors.lastname: Findley
authors.forename: H K
authors.initials: HK
authors.lastname: Iversen
authors.forename: D
authors.initials: D
authors.lastname: Melchart
authors.forename: H M
authors.initials: HM
authors.lastname: Sahlender
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018170:Sumatriptan
chemical_list: D007211:Indoles; D013449:Sulfonamides; D018170:Sumatriptan